Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Clonal Evolution × Lymphoid × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1

Interventions

Rituximab 628 Cyclophosphamide 568 Vincristine 315 Doxorubicin 277 Etoposide 274 Cytarabine 239 Filgrastim 225 Prednisone 222 Methotrexate 205 fludarabine phosphate 199 Dexamethasone 189 fludarabine 158 Radiotherapy 148 Peripheral Blood Stem Cell Transplantation 140 Lenalidomide 126 Granulocyte Colony-Stimulating Factor 124 Bendamustine Hydrochloride 115 Melphalan 113 Bortezomib 106 ibrutinib 99 Busulfan 97 Whole-Body Irradiation 95 Mycophenolic Acid 90 Tacrolimus 76 Gemcitabine 74 Cyclosporine 74 Ifosfamide 72 Alemtuzumab 71 Leucovorin 68 Carmustine 68

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03521596 2025-11-18

FIL_BIOWM

Fondazione Italiana Linfomi - ETS

Waldenstrom Macroglobulinemia, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡